Use of urinary metabolomics to evaluate the effect of hyperuricemia on the kidney

Food and Chemical Toxicology

Volumn 74, Issue , 2014, Pages 35-44

  Huang, Chi Chang ^a   Lou, Bih Show ^b   Hsu, Feng Lin ^c   Hou, Chia Chung ^a  

^a NATIONAL TAIWAN SPORT UNIVERSITY   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Hyperuricemia; IL 6 STAT3 signaling; Kidney injury; Urinary metabolomics

Indexed keywords

ALBUMIN; CREATININE; INTERLEUKIN 6; OTERACIL POTASSIUM; STAT3 PROTEIN; URIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ENERGY METABOLISM; GLOMERULAR DYSFUNCTION; HYPERURICEMIA; INFLAMMATION; KIDNEY FUNCTION; KIDNEY INJURY; MALE; MASS FRAGMENTOGRAPHY; METABOLITE; METABOLOMICS; MOUSE; NEPHRON; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PROTEIN URINE LEVEL; PROTEINURIA; REPRODUCIBILITY; UREA NITROGEN BLOOD LEVEL; URIC ACID BLOOD LEVEL; URIC ACID URINE LEVEL; URINALYSIS; ACUTE KIDNEY INJURY; ANIMAL; BLOOD; COMPLICATION; DRUG EFFECTS; INSTITUTE FOR CANCER RESEARCH MOUSE; KIDNEY; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROCEDURES; SIGNAL TRANSDUCTION; URINE;

ACUTE KIDNEY INJURY; ANIMALS; BLOOD UREA NITROGEN; CREATININE; HYPERURICEMIA; INTERLEUKIN-6; KIDNEY; MALE; METABOLOMICS; MICE, INBRED ICR; NEPHRONS; PROTEINURIA; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; URIC ACID;

EID: 84907661551     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2014.08.017     Document Type: Article

References (52)

1. Bellomo G., Venanzi S., Verdura C., Saronio P., Esposito A., Timio M. Association of uric acid with change in kidney function in healthy normotensive individuals. Am. J. Kidney Dis 2010, 56:264-272.
2. Bonventre J.V., Zuk A. Ischemic acute renal failure: an inflammatory disease?. Kidney Int 2004, 66:480-485.
3. Burtscher I.M., Holtås S. Proton magnetic resonance spectroscopy in brain tumours: clinical applications. Neuroradiology 2001, 43:345-352.
4. Chuang H.L., Huang Y.T., Chiu C.C., Liao C.D., Hsu F.L., Huang C.C., et al. Metabolomics characterization of energy metabolism reveals glycogen accumulation in gut-microbiota-lacking mice. J. Nutr. Biochem 2012, 23:752-758.
5. Dunckley T., Coon K.D., Stephan D.A. Discovery and development of biomarkers of neurological disease. Drug Discov. Today 2005, 10:326-334.
6. Eriksson L., Johansson E., Kettaneh-Wold N., Trygg J., Wikström C., Wold S. Multi- and Megavariate Data Analysis (Part I -Basics and Principles and Applications) 2006, Umetrics AB, Umea.
7. Fiehn O., Kopka J., Dörmann P., Altmann T., Trethewey R.N., Willmitzer L. Metabolite profiling for plant functional genomics. Nat. Biotechnol 2000, 18:1157-1161.
8. Friedewald J.J., Rabb H. Inflammatory cells in ischemic acute renal failure. Kidney Int 2004, 66:486-491.
9. Gartland K.P., Bonner F.W., Nicholson J.K. Investigations into the biochemical effects of region-specific nephrotoxins. Mol. Pharmacol 1989, 35:242-250.
10. Gartland K.P., Sanins S.M., Nicholson J.K., Sweatman B.C., Beddell C.R., Lindon J.C. Pattern recognition analysis of high resolution 1H NMR spectra of urine. A nonlinear mapping approach to the classification of toxicological data. NMR Biomed 1990, 3:166-172.
11. Gartland K.P., Beddell C.R., Lindon J.C., Nicholson J.K. Application of pattern recognition methods to the analysis and classification of toxicological data derived from proton nuclear magnetic resonance spectroscopy of urine. Mol. Pharmacol 1991, 39:629-642.
12. Hagberg G. From magnetic resonance spectroscopy to classification of tumors. A review of pattern recognition methods. NMR Biomed 1998, 11:148-156.
13. He J.C., Chuang P.Y., Ma'ayan A., Iyengar R. Systems biology of kidney diseases. Kidney Int 2012, 81:22-39.
14. Huang C.C., Lin W.T., Hsu F.L., Tsai P.W., Hou C.C. Metabolomics investigation of exercise-modulated changes in metabolism in rat liver after exhaustive and endurance exercises. Eur. J. Appl. Physiol 2010, 108:557-566.
15. Ibrahim S.M., Gold R. Genomics, proteomics, metabolomics: what is in a word for multiple sclerosis?. Curr. Opin. Neurol 2005, 18:231-235.
16. Idle J.R., Gonzalez F.J. Metabolomics. Cell Metab 2007, 6:348-351.
17. Jalal D.I., Maahs D.M., Hovind P., Nakagawa T. Uric acid as a mediator of diabetic nephropathy. Semin. Nephrol 2011, 31:459-465.
18. Johnson R.J., Kang D.H., Feig D., Kivlighn S., Kanellis J., Watanabe S., et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?. Hypertension 2003, 41:1183-1190.
19. Kang D.H., Chen W. Uric acid and chronic kidney disease: new understanding of an old problem. Semin. Nephrol 2011, 31:447-452.
20. Kang D.H., Nakagawa T., Feng L., Watanabe S., Han L., Mazzali M., et al. A role for uric acid in the progression of renal disease. J. Am. Soc. Nephrol 2002, 13:2888-2897.
21. Khosla U.M., Zharikov S., Finch J.L., Nakagawa T., Roncal C., Mu W., et al. Hyperuricemia induces endothelial dysfunction. Kidney Int 2005, 67:1739-1742.
22. Kielar M.L., John R., Bennett M., Richardson J.A., Shelton J.M., Chen L., et al. Maladaptive role of IL-6 in ischemic acute renal failure. J. Am. Soc. Nephrol 2005, 16:3315-3325.
23. Klein C.L., Hoke T.S., Fang W.F., Altmann C.J., Douglas I.S., Faubel S. Interleukin-6 mediates lung injury following ischemic acute kidney injury or bilateral nephrectomy. Kidney Int 2008, 74:901-909.
24. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
25. Lindon J.C., Holmes E., Nicholson J.K. Metabonomics techniques and applications to pharmaceutical research & development. Pharm. Res 2006, 23:1075-1088.
26. Lyngdoh T., Marques-Vidal P., Paccaud F., Preisig M., Waeber G., Bochud M., et al. Elevated serum uric acid is associated with high circulating inflammatory cytokines in the population-based Colaus study. PLoS ONE 2011, 6:e19901.
27. Maples K.R., Mason R.P. Free radical metabolite of uric acid. J. Biol. Chem 1988, 263:1709-1712.
28. Martinon F. Mechanisms of uric acid crystal-mediated autoinflammation. Immunol. Rev 2010, 233:218-232.
29. Martinon F., Pétrilli V., Mayor A., Tardivel A., Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006, 440:237-241.
30. Mäkinen V.P., Soininen P., Forsblom C., Parkkonen M., Ingman P., Kaski K., et al. 1H NMR metabonomics approach to the disease continuum of diabetic complications and premature death. Mol. Syst. Biol 2008, 4:167.
31. Meotti F.C., Jameson G.N., Turner R., Harwood D.T., Stockwell S., Rees M.D., et al. Urate as a physiological substrate for myeloperoxidase: implications for hyperuricemia and inflammation. J. Biol. Chem 2011, 286:12901-12911.
32. Nechemia-Arbely Y., Barkan D., Pizov G., Shriki A., Rose-John S., Galun E., et al. IL-6/IL-6R axis plays a critical role in acute kidney injury. J. Am. Soc. Nephrol 2008, 19:1106-1115.
33. Peters G.J., Noordhuis P., Van Kuilenburg A.B., Schornagel J.H., Gall H., Turner S.L., et al. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors. Cancer Chemother. Pharmacol 2003, 52:1-12.
34. Ragan H.A. Markers of renal function and injury. The Clinical Chemistry of Laboratory Animals 1989, 321-343. McGraw Hill, New York. W.F. Loeb, F.W. Quimby (Eds.).
35. Roncal C.A., Mu W., Croker B., Reungjui S., Ouyang X., Tabah-Fisch I., et al. Effect of elevated serum uric acid on cisplatin-induced acute renal failure. Am. J. Physiol. Renal Physiol 2007, 292:F116-F122.
36. Ruggiero C., Cherubini A., Ble A., Bos A.J., Maggio M., Dixit V.D., et al. Uric acid and inflammatory markers. Eur. Heart J. 2006, 27:1174-1181.
37. Santos C.X., Anjos E.I., Augusto O. Uric acid oxidation by peroxynitrite: multiple reactions, free radical formation, and amplification of lipid oxidation. Arch. Biochem. Biophys 1999, 372:285-294.
38. Sautin Y.Y., Johnson R.J. Uric acid: the oxidant-antioxidant paradox. Nucleosides Nucleotides Nucleic Acids 2008, 27:608-619.
39. Shekarriz B., Stoller M.L. Uric acid nephrolithiasis: current concepts and controversies. J. Urol 2002, 168:1307-1314.
40. Shirasaka T., Nakano K., Takechi T., Satake H., Uchida J., Fujioka A., et al. Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 1996, 56:2602-2606.
41. Smith L.M., Maher A.D., Want E.J., Elliott P., Stamler J., Hawkes G.E., et al. Large-scale human metabolic phenotyping and molecular epidemiological studies via 1H NMR spectroscopy of urine: investigation of borate preservation. Anal. Chem 2009, 81:4847-4856.
42. Stavric B., Nera E.A. Use of the uricase-inhibited rat as an animal model in toxicology. Clin. Toxicol 1978, 13:47-74.
43. Suganuma M., Okabe S., Kurusu M., Iida N., Ohshima S., Saeki Y., et al. Discrete roles of cytokines, TNF-alpha, IL-1, IL-6 in tumor promotion and cell transformation. Int. J. Oncol 2002, 20:131-136.
44. Tung Y.T., Wu J.H., Huang C.C., Peng H.C., Chen Y.L., Yang S.C., et al. Protective effect of Acacia confusa bark extract and its active compound gallic acid against carbon tetrachloride-induced chronic liver injury in rats. Food Chem. Toxicol 2009, 47:1385-1392.
45. Tung Y.T., Hsu C.A., Chen C.S., Yang S.C., Huang C.C., Chang S.T. Phytochemicals from Acacia confusa heartwood extracts reduce serum uric acid levels in oxonate-induced mice: their potential use as xanthine oxidase inhibitors. J. Agric. Food Chem 2010, 58:9936-9941.
46. van Groeningen C.J., Peters G.J., Schornagel J.H., Gall H., Noordhuis P., de Vries M.J., et al. Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J. Clin. Oncol 2000, 18:2772-2779.
47. Vásquez-Vivar J., Santos A.M., Junqueira V.B., Augusto O. Peroxynitrite-mediated formation of free radicals in human plasma: EPR detection of ascorbyl, albumin-thiyl and uric acid-derived free radicals. Biochem. J. 1996, 314:869-876.
48. Woodcock J. The prospects for "personalized medicine" in drug development and drug therapy. Clin. Pharmacol. Ther 2007, 81:164-169.
49. Wu L.L., Wu J.T. Serum uric acid is a marker of inflammation and a marker predicting the risk of developing CVD, stroke, renal failure and cancer. J. Biomed. Lab. Sci 2008, 20:1-5.
50. Yamashita T., Ueda Y., Fuji N., Itoh T., Kurioka H., Shirasaka T., et al. Potassium oxonate, an enzyme inhibitor compounded in S-1, reduces the suppression of antitumor immunity induced by 5-fluorouracil. Cancer Chemother. Pharmacol 2006, 58:183-188.
51. Yoshisue K., Masuda H., Matsushima E., Ikeda K., Nagayama S., Kawaguchi Y. Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent (drug combination of tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate) to rats. Drug Metab. Dispos 2000, 28:1162-1167.
52. Zhou Y., Fang L., Jiang L., Wen P., Cao H., He W., et al. Uric acid induces renal inflammation via activating tubular NF-κB signaling pathway. PLoS ONE 2012, 7. e39738.